Viable disc regenerative composition and method of manufacture and use

Inventors

Temple, Harry Thomas • Ganey, Timothy • Gonzalez, Stephanie • Anderson, Tracy Scott • Namin, Shabnam

Assignees

Vivex Biologics Group Inc

Interested in licensing this patent?

MTEC can help explore whether this patent might be available for licensing for your application.

Publication Number

US-11606953-B2

Patent

Publication Date

2023-03-21

Expiration Date


Abstract

A viable disc regenerative composition has a micronized material of nucleus pulposus and a biological composition made from a mixture of mechanically selected allogeneic biologic material derived from bone marrow having non-whole cellular components including vesicular components and active and inactive components of biological activity, cell fragments, cellular excretions, cellular derivatives, and extracellular components; and wherein the mixture is compatible with biologic function and further includes non-expanded whole cells. The biological composition is predisposed to demonstrate or support elaboration of active volume or spatial geometry consistent in morphology with that of disc tissue. The viable disc regenerative composition extends regenerative resonance that compliments or mimics disc tissue complexity.

Core Innovation

The invention provides a viable disc regenerative composition that combines a mechanically selected, allogeneic bone-marrow-derived biological mixture with non-whole cellular components and optionally non-expanded whole cells, and a composition of micronized nucleus pulposus. The micronized nucleus pulposus is rehydrated to form a high-viscosity, injectable composite that supports disc-mimicking tissue geometry and proteoglycan replenishment.

The bone-marrow-derived biologic mixture is prepared from cadaver T9–L5 spine-derived bone marrow and includes cellular and non-cellular components separated from each other. A key aspect of the composition is the inclusion of non-whole cellular components such as vesicular/secreted/extracellular components, including active and inactive biological activity components, cell fragments, and cellular excretions/derivatives.

The bone-marrow-derived cellular and non-cellular components are cryopreserved in a polyampholyte cryoprotectant and frozen, and packaging is configured so that the cryopreserved cell component and the dehydrated micronized nucleus pulposus are kept as separate components prior to use. Upon thaw/rehydration, the components are introduced for injection as an injectable composite.

Claims Coverage

The document provides two independent claims. Across these claims, the main inventive features include multi-cycle tumbling/sieving/decanting of cadaver cortical-cancellous bone chips, downstream concentration and separation of cellular vs non-cellular marrow components, cryoprotection in a polyampholyte and freezing, inclusion of micronized nucleus pulposus particles sized to less than 300 μm, and separate packaging of the cryopreserved mixture and the micronized nucleus pulposus composition in one independent claim.

Four-cycle tumbling, sieving and decanting of cadaver cortical-cancellous chips

Obtaining bone marrow from cadaverous bone cut to form bulk cortical-cancellous bone chips and separating cellular and non-cellular components of bone marrow utilizing four cycles of tumbling, sieving and decanting, including discarding decanted fluid from cycle 1 and combining the decanted fluids from cycles 2-4 to form a decanted fluid containing cellular and non-cellular components.

Concentration and centrifugation/filtering of marrow components

Concentrating the cellular and non-cellular components from the decanted fluid by centrifugation and filtering.

Density gradient separation of cellular and non-cellular components

Separating the cellular and non-cellular components of bone marrow by density gradient centrifugation.

Polyampholyte cryoprotectant suspension and freezing

Collecting cells or non-cellular components or combinations thereof, washing the collected cells or non-cellular components or combinations thereof to create a mixture, suspending the mixture in a polyampholyte cryoprotectant, and freezing the mixture.

Addition of micronized nucleus pulposus particles below 300 μm

Adding to the frozen mixture a composition of micronized nucleus pulposus having particles in the size range of less than 300 μm.

Separate packaging of cryopreserved mixture and micronized nucleus pulposus

Packaging separately (a) the mixture and (b) a composition of micronized nucleus pulposus having particles in the size range of less than 300 μm.

The independent claims collectively cover making a viable disc regenerative composition by processing cadaver cortical-cancellous bone chips through four cycles of tumbling/sieving/decanting, concentrating and density-gradient separating marrow cellular and non-cellular components, washing and suspending them in a polyampholyte cryoprotectant followed by freezing, and adding micronized nucleus pulposus particles sized less than 300 μm; one independent claim additionally requires separate packaging of the cryopreserved mixture and the micronized nucleus pulposus composition.

Stated Advantages

Supports disc-mimicking tissue geometry consistent with disc tissue.

Supports proteoglycan replenishment.

Maintains reported viability and recovery after thawing.

Provides an injectable, high-viscosity composite via rehydrated micronized nucleus pulposus.

Documented Applications

Used as a viable disc regenerative composition, in which thaw/rehydrated components are prepared for injection.

JOIN OUR MAILING LIST

Stay Connected with MTEC

Keep up with active and upcoming solicitations, MTEC news and other valuable information.